Filing Details

Accession Number:
0001209191-21-059552
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-10-05 17:04:01
Reporting Period:
2021-10-01
Accepted Time:
2021-10-05 17:04:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1000694 Novavax Inc NVAX Biological Products, (No Disgnostic Substances) (2836) 222816046
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1342826 C Stanley Erck C/O Novavax, Inc.
21 Firstfield Road
Gaithersburg MD 20878
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-10-01 14,000 $27.60 37,879 No 4 M Direct
Common Stock Acquisiton 2021-10-01 35,000 $27.00 72,879 No 4 M Direct
Common Stock Disposition 2021-10-01 703 $164.74 72,176 No 4 S Direct
Common Stock Disposition 2021-10-01 904 $165.68 71,272 No 4 S Direct
Common Stock Disposition 2021-10-01 1,100 $166.62 70,172 No 4 S Direct
Common Stock Disposition 2021-10-01 2,801 $167.88 67,371 No 4 S Direct
Common Stock Disposition 2021-10-01 1,959 $169.05 65,412 No 4 S Direct
Common Stock Disposition 2021-10-01 901 $170.07 64,511 No 4 S Direct
Common Stock Disposition 2021-10-01 2,602 $171.34 61,909 No 4 S Direct
Common Stock Disposition 2021-10-01 4,103 $172.02 57,806 No 4 S Direct
Common Stock Disposition 2021-10-01 3,002 $173.16 54,804 No 4 S Direct
Common Stock Disposition 2021-10-01 5,853 $174.30 48,951 No 4 S Direct
Common Stock Disposition 2021-10-01 3,602 $175.15 45,349 No 4 S Direct
Common Stock Disposition 2021-10-01 2,601 $176.24 42,748 No 4 S Direct
Common Stock Disposition 2021-10-01 6,227 $177.37 36,521 No 4 S Direct
Common Stock Disposition 2021-10-01 4,604 $178.27 31,917 No 4 S Direct
Common Stock Disposition 2021-10-01 1,323 $179.29 30,594 No 4 S Direct
Common Stock Disposition 2021-10-01 2,541 $180.42 28,053 No 4 S Direct
Common Stock Disposition 2021-10-01 1,600 $181.21 26,453 No 4 S Direct
Common Stock Disposition 2021-10-01 300 $182.40 26,153 No 4 S Direct
Common Stock Disposition 2021-10-01 192 $183.61 25,961 No 4 S Direct
Common Stock Disposition 2021-10-01 8 $185.71 25,953 No 4 S Direct
Common Stock Disposition 2021-10-01 100 $187.95 25,853 No 4 S Direct
Common Stock Disposition 2021-10-01 1,502 $189.47 24,351 No 4 S Direct
Common Stock Disposition 2021-10-01 472 $190.63 23,879 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2021-10-01 14,000 $0.00 14,000 $27.60
Common Stock Stock Option (Right to Buy) Disposition 2021-10-01 35,000 $0.00 35,000 $27.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
68,499 2027-12-15 No 4 M Direct
10,829 2026-11-14 No 4 M Direct
Footnotes
  1. The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $164.26 to $165.20, inclusive. The reporting person undertakes to provide to Novavax, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission (the "SEC"), upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  3. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.30 to $166.24, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  4. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.30 to $167.16, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  5. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.31 to $168.27, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  6. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.50 to $169.45, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  7. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.59 to $170.39, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  8. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.65 to $171.62, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  9. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $171.66 to $172.65, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  10. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $172.67 to $173.63, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  11. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.72 to $174.71, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  12. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.74 to $175.72, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  13. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.79 to $176.55, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  14. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.80 to $177.75, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  15. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.82 to $178.75, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  16. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.87 to $179.84, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  17. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.88 to $180.87, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  18. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $180.88 to $181.71, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  19. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $181.88 to $182.83, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  20. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $183.60 to $183.62, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  21. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $189.07 to $189.95, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  22. The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $190.63 to $190.95, inclusive. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the SEC, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
  23. Twenty-five percent (25%) of the shares subject to this option grant under the Company Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), vested on the first anniversary of the December 15, 2017 grant date, and the remaining seventy-five percent (75%) of the shares vested or will vest in equal monthly installments over the following three (3) years subject to continued employment through each such vesting date.
  24. Vesting of the shares subject to this option grant under the Plan were subject to the satisfaction of both (1) a time-based vesting requirement, pursuant to which twenty-five percent (25%) of the shares vested on the first anniversary of the November 14, 2016 grant date, and the remaining seventy-five percent (75%) of the shares vested in equal monthly installments on the first of each month over the following three (3) years subject to continued employment through such vesting date, and (2) a performance-based vesting requirement, pursuant to which 33.33%, 33.33%, and 33.34% of the shares vested, if at any time during the four-year period from the November 14, 2016 grant date, the volume-weighted average stock price of the Company's common stock met or exceeded $80.00, $120.00, or $160.00, respectively, for twenty (20) consecutive trading days. The Company's common stock did not meet $160.00 for twenty (20) consecutive trading days and therefore 9,171 shares were cancelled.